Literature DB >> 9811680

Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells.

T Rothmann1, A Hengstermann, N J Whitaker, M Scheffner, H zur Hausen.   

Abstract

The 55-kDa E1B protein of adenovirus, which binds to and inactivates the tumor suppressor protein p53, is not expressed in the adenoviral mutant termed ONYX-015 (i.e., dl1520). It was reported that the mutant virus due to a deletion in E1B is able to replicate only in cells deficient for wild-type p53. Accordingly, dl1520 is currently being evaluated as a potential tool in the therapy of p53 deficient cancers. In contrast, we report here that dl1520 replicates independently of the p53 status in various tumor cell lines (U87, RKO, A549, H1299, and U373). In addition, the inhibition of p53-mediated transcriptional activation in wild-type p53 containing U2OS cells, by overexpression of a transdominant negative p53 mutant, did not render the cells permissive for dl1520 replication. Finally, we show that, depending on the multiplicity of infection, the deleted virus is able to replicate in and to kill primary human cells. Thus, the molecular basis for the growth differences of dl1520 within different cell types remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811680      PMCID: PMC110441     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Role of the adenovirus early region 1B tumor antigens in transformation and lytic infection.

Authors:  R Bernards; M G de Leeuw; A Houweling; A J van der Eb
Journal:  Virology       Date:  1986-04-15       Impact factor: 3.616

2.  Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport.

Authors:  L E Babiss; H S Ginsberg; J E Darnell
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

3.  Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells.

Authors:  P Sarnow; Y S Ho; J Williams; A J Levine
Journal:  Cell       Date:  1982-02       Impact factor: 41.582

4.  Functional analysis of adenovirus-5 host-range deletion mutants defective for transformation of rat embryo cells.

Authors:  T Shenk; N Jones; W Colby; D Fowlkes
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1980

5.  Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff.

Authors:  D N Halbert; J R Cutt; T Shenk
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

6.  Structure and transcription of human papillomavirus sequences in cervical carcinoma cells.

Authors:  E Schwarz; U K Freese; L Gissmann; W Mayer; B Roggenbuck; A Stremlau; H zur Hausen
Journal:  Nature       Date:  1985 Mar 7-13       Impact factor: 49.962

7.  Effect of adeno-associated virus on transformation of NIH 3T3 cells by ras gene and on tumorigenicity of an NIH 3T3 transformed cell line.

Authors:  E Katz; B J Carter
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

8.  Adenovirus early region 1B 58,000-dalton tumor antigen is physically associated with an early region 4 25,000-dalton protein in productively infected cells.

Authors:  P Sarnow; P Hearing; C W Anderson; D N Halbert; T Shenk; A J Levine
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

9.  Adenovirus type 5 early region 1b gene product is required for efficient shutoff of host protein synthesis.

Authors:  L E Babiss; H S Ginsberg
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

10.  The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs.

Authors:  S Pilder; M Moore; J Logan; T Shenk
Journal:  Mol Cell Biol       Date:  1986-02       Impact factor: 4.272

View more
  81 in total

1.  p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication.

Authors:  J N Harada; A J Berk
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Roles for the E4 orf6, orf3, and E1B 55-kilodalton proteins in cell cycle-independent adenovirus replication.

Authors:  F D Goodrum; D A Ornelles
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 3.  Replication-selective adenoviruses as oncolytic agents.

Authors:  C Heise; D H Kirn
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

4.  Effects of mutations in the adenoviral E1B 55-kilodalton protein coding sequence on viral late mRNA metabolism.

Authors:  Ramon A Gonzalez; S J Flint
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 5.  Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

Authors:  B R Dix; S J Edwards; A W Braithwaite
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

6.  Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications.

Authors:  B L Hodges; H K Evans; R S Everett; E Y Ding; D Serra; A Amalfitano
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes.

Authors:  Sara J Edwards; Brett R Dix; Colleen J Myers; Deirdre Dobson-Le; Lily Huschtscha; Merilyn Hibma; Janice Royds; Antony W Braithwaite
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 8.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

9.  Reduced infectivity of adenovirus type 5 particles and degradation of entering viral genomes associated with incomplete processing of the preterminal protein.

Authors:  Sayuri E Kato; Jasdave S Chahal; S J Flint
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

10.  An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.

Authors:  Charles M Rudin; Ezra E W Cohen; Vassiliki A Papadimitrakopoulou; Sol Silverman; Wendy Recant; Adel K El-Naggar; Kirsten Stenson; Scott M Lippman; Waun Ki Hong; Everett E Vokes
Journal:  J Clin Oncol       Date:  2003-11-03       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.